Terumo BCT Inc.

Terumo BCT Inc., operating as Terumo Bct, Inc. Division and doing business as Caridianbct Inc., is a foreign-owned manufacturer of blood and cell processing equipment and consumables that sells specialized medical devices, apheresis systems, sterile tubing welders, blood bag systems, and related preventative maintenance services to federal health and defense agencies as a prime contractor exclusively. The company competes in full-and-open procurements without set-aside designations across its entire federal footprint.

Headquartered in Lakewood, Colorado, Terumo BCT manufactures surgical and medical instruments (489 awards across NAICS 339112 — Surgical and Medical Instrument Manufacturing) and diagnostic substances (98 awards under NAICS 325413 — In-Vitro Diagnostic Substance Manufacturing). The vendor's concrete capability portfolio centers on Spectra Optia apheresis systems, Trima Accel blood cell processors, COBE 2991 cell processors, Optia automated blood cell separators, and related consumables — Trima Accel RBC/Platelet/Plasma sets, blood bag systems, tubing welders (TSCD II sterile tubing welders), and maintenance services. Representative prime work includes a $102,680 purchase order from Veterans Integrated Service Network 9 (Department of Veterans Affairs) for a Spectra Optia apheresis machine (July 2026), a $281,429 BPA call from the Defense Health Agency for V7 Trima Accel RBC/Platelet/Plasma sets (September 2024), and a $230,922 purchase order from the National Institute of Allergy and Infectious Diseases for ten SCD IIB sterile tubing welders supporting vaccine research (July 2023).

Customer concentration sits with defense medical and research agencies. The Defense Logistics Agency Troop Support Medical leads by award count (273 awards, $707 thousand combined potential value), but the Defense Health Agency (85 awards, $23.8 million combined potential value), the Department of the Navy Bureau of Medicine and Surgery (175 awards, $23 million), and the Department of the Army Medical Command (110 awards, $20.9 million) dominate by dollar magnitude — together accounting for 86% of combined potential value. The National Institutes of Health Clinical Center represents the largest civilian customer with 52 awards and $2.6 million in combined potential value. Across the portfolio, the top five agencies account for 70% of awards and the top customer cluster anchors 86% of dollar value, reflecting heavy concentration in military healthcare and defense medical logistics. Awards cluster under medical PSC categories: Medical And Surgical Instruments, Equipment, And Supplies (625 awards) and Laboratory Equipment And Supplies (121 awards).

Terumo BCT's parent-vehicle footprint centers on single-award and multi-award indefinite delivery contracts with defense agencies. The Indefinite Delivery Contract N6264509D5015 (Navy) supports 36 task orders with $862 thousand combined potential value; N6264513D5049 (Navy) carries 19 task orders and $930 thousand; and N6264519D5002 (Defense Health Agency) carries 16 task orders and $652 thousand. Blanket Purchase Agreement HT001420A0013 with the Defense Health Agency represents 11 task orders and $2.1 million in combined potential value, while BPA W81XWH16A0009 with the Army Medical Command supports 16 task orders worth $104 thousand. The vendor does not hold seats on government-wide vehicles (GWACs or schedule contracts); instead it competes through agency-specific IDVs and direct purchase orders.

Activity has declined in recent years — 17 awards in 2022, declining to 3 awards in the first half of 2026 — though the source data represent a 33-year snapshot beginning September 1993, with the bulk of awards concentrated in the defense medical procurement stream. Fourteen awards with combined potential value of $1.5 million face ultimate completion within the next twenty-four months, creating moderate recompete exposure. The vendor operates exclusively as a prime contractor (100% of awards); no subcontractor role was identified in the source data. Terumo BCT competes in unrestricted procurements; all awards carry no set-aside designations, reflecting both the specialized and proprietary nature of its medical equipment and the vendor's established position as the incumbent supplier for many federal blood processing and cellular therapy applications.